Among the general population, Bredella and colleagues demonstrated reductions in intrahepatic lipid among men with abdominal obesity, not selected for NAFLD, who received 6 months of recombinant human GH (rhGH) compared with those receiving placebo [89]. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.